<DOC>
	<DOCNO>NCT00365183</DOCNO>
	<brief_summary>The goal study : - determine combination two drug , motexafin gadolinium pemetrexed , may effective treatment patient non-small cell lung cancer ( NSCLC ) one previous chemotherapy regimen include platinum contain drug cisplatin carboplatin . - assess response treatment patient NSCLC six month begin study treatment .</brief_summary>
	<brief_title>Trial Motexafin Gadolinium Pemetrexed ( AlimtaÂ® ) Second Line Treatment Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>18 year old Stage IIIb , metastatic , recurrent NSCLC patient receive one prior platinumbased chemotherapy regimen ECOG performance status score 0 1 Laboratory value indicate inadequate function bone marrow , liver , kidney Symptomatic uncontrolled brain metastasis Evidence meningeal metastasis &gt; 1 prior regimen ( count adjuvant neoadjuvant cytotoxic chemotherapy complete &gt; 12 month prior regiment ) Medical condition would increase risk treat motexafin gadolinium impair ability complete study procedure assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Metastatic Lung Cancer</keyword>
	<keyword>Inoperable Lung Cancer</keyword>
	<keyword>Advanced Lung Cancer</keyword>
	<keyword>Large Cell Lung Cancer</keyword>
	<keyword>Adenocarcinoma , lung</keyword>
	<keyword>Squamous Cell Carcinoma , lung</keyword>
	<keyword>Squamous Cell Lung Cancer</keyword>
	<keyword>Large Cell Carcinoma , lung</keyword>
	<keyword>Cancer Lung</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Bronchogenic</keyword>
</DOC>